Table 1.
Comparative analysis of demographic, clinical and laboratory data among study groups
| Variable | DM (n = 425) | New onset DM (n = 384) | IGT (n = 560) | IFG (n = 376) | NGT (n = 782) |
|---|---|---|---|---|---|
| Age (yrs) |
65.5 ± 9.5* |
65.3 ± 10.4* |
62.3 ± 10.3* |
58.2 ± 11.0 |
57.0 ± 11.3 |
| Male – no. (%) |
241 (56.7)* |
237 (61.6)* |
395 (70.5)* |
316 (82.4) |
618 (79.0) |
| Smoking – no. (%) |
166 (39.1)* |
182 (47.4)* |
319 (56.9)* |
245 (65.1) |
533 (68.2) |
| Hypertension – no. (%) |
320 (75.3)* |
218 (56.9)* |
302 (53.9)* |
167 (44.3) |
325 (41.6) |
| Hyperlipidaemia – no. (%) |
232 (54.5) |
200 (52.1) |
295 (52.6) |
208 (55.2) |
411 (52.5) |
| Peripheral vascular disease – no. (%) |
42 (9.9) |
41 (10.8) |
48 (8.5) |
23 (6.1) |
61 (7.8) |
| Creatinine on admission (μmol\L) |
104.3 ± 86.6* |
92.1 ± 39.2* |
85.9 ± 34.0 |
80.3 ± 18.7* |
85.5 ± 42.5 |
| GFR (mL/min/1.73 m2) |
73.3 ± 26.7* |
77.6 ± 25.6* |
84.5 ± 25.2* |
92.5 ± 24.5* |
89.2 ± 25.6 |
| Contrast-induced nephropathy – no. (%) |
110 (25.8)* |
127 (33.2)* |
150 (26.8)* |
79 (21.1) |
133 (17.0) |
| Previous myocardial infarction – no. (%) |
113 (26.5)* |
75 (19.6) |
95 (16.9) |
61 (16.3) |
132 (16.9) |
| Previous CABG – no. (%) |
16 (3.8) |
10 (2.7) |
12 (2.2) |
10 (2.7) |
26 (3.3) |
| Previous PCI – no. (%) |
63 (14.8)* |
31 (8.2) |
54 (9.6) |
26 (7.0) |
66 (8.4) |
| Glucose on admission (mmol/L) |
12.2 ± 5.4* |
9.6 ± 4.1* |
7.8 ± 2.5* |
7.2 ± 2.0 |
7.2 ± 2.2 |
| Pain duration (hours) |
7.9 ± 9.9* |
7.9 ± 10.5* |
5.8 ± 6.6 |
5.7 ± 5.9 |
5.9 ± 7.4 |
| Killip-class on admission |
1.3 ± 0.7* |
1.4 ± 0.8* |
1.3 ± 0.6* |
1.2 ± 0.5 |
1.2 ± 0.5 |
| Anterior infarction – no. (%) |
144 (33.8) |
150 (39.1)* |
195 (34.8) |
143 (37.9)* |
242 (31.0) |
| Ejection fraction (%) |
42.0 ± 8.4* |
42.8 ± 8.3* |
43.8 ± 7.8* |
44.9 ± 7.7 |
45.7 ± 7.0 |
| Fibrinolysis – no. (%) |
10 (2.3) |
10 (2.5) |
21 (3.8) |
8 (2.1) |
31 (4.0) |
| GP IIb/IIIa – inhibitor – no. (%) |
68 (16.0)* |
66 (17.3)* |
80 (14.3) |
58 (15.5)* |
84 (10.8) |
| Beta-adrenergic blocker – no. (%) |
372 (87.6) |
338 (88.1) |
498 (88.9) |
327 (87.0) |
702 (89.8) |
| ACE-inhibitor/ARB – no. (%) |
369 (86.9) |
328 (85.4) |
483 (86.2) |
320 (85.2) |
672 (85.9) |
| Aspirin – no. (%) |
414 (97.4) |
376 (98.0) |
549 (98.0) |
369 (98.2) |
769 (98.3) |
| Statin – no. (%) |
357 (83.9) |
323 (84.0) |
471 (84.1) |
312 (83.1) |
658 (84.2) |
| Clopidogrel/Ticlopidine – no. (%) |
369 (86.9) |
335 (87.2) |
488 (87.1) |
325 (86.4) |
683 (87.4) |
| Multivessel coronary artery disease –no (%) |
322 (75.8)* |
252 (65.7)* |
346 (61.7) |
222 (59.1) |
456 (58.3) |
| Incomplete revascularization – no. (%) |
240 (56.5)* |
177 (46.1) |
264 (47.1) |
172 (45.8) |
328 (41.9) |
| TIMI flow <3 after PCI of IRA – no. (%) |
63 (14.9)* |
70 (18.1)* |
72 (12.8) |
45 (12.1) |
77 (9.8) |
| Hospitalization time (days) | 9.8 ± 7.9* | 10.3 ± 6.2* | 8.9 ± 4.6* | 7.7 ± 2.6 | 7.6 ± 4.3 |
Values presented as means ± SD or percentage of subjects. ARB = angiotensin receptor blockers; CABG = coronary artery by-pass grafting; DM = type 2 diabetes mellitus; GFR = glomerular filtration rate; GP IIb/IIIa = glycoprotein IIb/IIIa; IGT = impaired glucose tolerance; IFG = impaired fasting glucose; NGT = normal glucose tolerance; IRA = infarct-related artery; PCI = percutaneous coronary intervention; TIMI = Thrombolysis in Myocardial Infarction.
* – p value <0.05 compared with normal glucose tolerance group (NGT).